+44 7723 059341
Media and feeds shape almost every upstream outcome – growth, viability, titre, product quality and batch-to-batch consistency. Z2 brings dedicated leadership experience in cell culture media and process development to help you choose, optimise and control the media behind your process.
Media development is treated as part of the process, not a separate exercise: media, feeds and process parameters are developed together, so improvements hold as the process scales.
What we do
- Cell culture media and feed optimisation
- Media/process integration, seeding and feeding strategies
- Raw-material strategy and variability management
- Metabolic interpretation of growth and productivity data
- Troubleshooting growth, viability, productivity and consistency
- DoE-based and data-driven media design, including AI/ML approaches
Why media matters
Typical antibody titres have risen from around 0.5 g/L in the 1980s to an industry average of about 2.5 g/L, with the best fed-batch processes now reaching 10 g/L.1,2 Much of that gain comes from media, feeds and process conditions.
4 → 10 g/L
One antibody process, by optimising feed, then medium, then pH and temperature3
2.5 g/L
Industry-average antibody titre today2
10 g/L
Best fed-batch titres today1
Where rushed timelines break
Media changed late, or optimised in isolation from the process, so gains at small scale fail to hold in the bioreactor.
Where Z2 helps
Structured, DoE-led media and feed work integrated with process parameters – supported by metabolic interpretation and, where it adds value, predictive modelling.
Sources
- Engineering in Life Sciences. Increased MSX level improves productivity in GS CHO cell lines (PMC7447880).
- BioProcess International. 30 years of upstream titer productivity improvements, March 2025.
- Intracellular response to process optimization, high-titer CHO process. PubMed 28941283 (4 to 10 g/L).
